Immune responses in the CNS are common, despite its perception as a site of immune privilege. These responses can be mediated by resident microglia and astrocytes, which are innate immune cells without direct counterparts in the periphery. Furthermore, CNS immune reactions often take place in virtual isolation from the innate/adaptive immune interplay that characterizes peripheral immunity. However, microglia and astrocytes also engage in significant cross-talk with CNS-infiltrating T cells and other components of the innate immune system. Here we review the cellular and molecular basis of innate immunity in the CNS and discuss what is known about how outcomes of these interactions can lead to resolution of infection, neurodegeneration, or neural repair depending on the context.

Immune privilege: CNS innate immune cells do not phone home
An essential function of innate immunity is to provide the informational input for adaptive immunity. In peripheral organs, innate DCs detect the presence and nature of pathogens (viral, bacterial, or protozoal; intracellular or extracellular) and, through the release of selective mediators, educate T cells about the specifics of pathogen threat. Once the T cell has been informed (primed and polarized), it is directed to the site that harbors the pathogen (1–4). Here other resident or infiltrating innate cells decode the expressed array of T cell cytokines and, in a perfect immunological world, carry out the appropriate host attack on pathogen (Figure 1).

Inflammation in the CNS: the role for DCs
DCs play a critical role in initiating T cell responses by taking up protein antigens in tissues, processing them into small peptides and then displaying them on their surface physically associated with MHC class II molecules. DCs migrate through afferent lymphatics to draining lymph nodes and present antigen to naive or memory T cells. Importantly, there is no evidence that DCs with such capacities reside in the healthy CNS parenchyma, nor do CNS resident immune cells prime naive T cells (reviewed in ref. 5). Cells carrying DC surface markers (e.g., CD11b, CD11c) are readily detected in the meningeal coverings of the CNS and in the choroid plexus, the site of cerebrospinal fluid synthesis (6). Although cells with DC markers are abundant in the inflamed CNS parenchyma, they are primarily observed after blood-brain barrier (BBB) disruption, suggesting that many are peripherally derived while others represent resident microglia induced to express such markers by locally expressed cytokines (7–10).

The lack of parenchymal DCs and the fact that no other parenchymal CNS cells fit the operational definition of a DC (antigen uptake, migration to draining lymph nodes, and presentation to naive T cells) constitute the cellular basis of CNS immune privilege. Immune privilege of the CNS, a holy concept whose definition has become swollen and imprecise over more than six decades can be reduced to two observations: (a) immunogens such as xenografts, viruses, or bacterial lysates fail to elicit adaptive immune responses following non-traumatic micro-injection into the CNS parenchyma and (b) peripheral immunization with the same immunogen leads to a brisk immune response to the CNS depot of antigen.

Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J Clin Invest. 2012;122(4):1164–1171. doi:10.1172/JCI58644.
Activation of caspase-1 is initiated by signaling from a second set of innate immune receptors, termed “nucleotide-binding domain leucine-rich repeat–containing (LRR-containing) receptors” (NLRs), whose function is dependent on the assembly of large (~700-kDa) complexes termed “inflammasomes” (23, 24). NLRs have been studied extensively in hematopoietic cells including myeloid lineage cells in the CNS such as microglia. Our understanding of specific NLR functions is encumbered by an unwieldy and ever-changing terminology. The largest NLR subfamily (with 14 members), and the one most pertinent for neuroinflammation, is designated the NACHT domain–, LRR domain–, and pyrin domain–containing protein (NALP) family (25). Inflammasomes, defined by their core NALPs, are activated by the cytoplasmic presence of specific microbial components, tissue-injury products, or inflammation-associated metabolic alterations including low cytosolic potassium (26). For NALP3 inflammasomes, effective stimuli include bacterial muramyl dipeptide, bacterial RNA, ATP, and uric acid. Inflammasomes recruit and activate caspase-1, thereby complementing TLR signaling to generate mature IL-1β and IL-18. Another family member, IL-33, is sequestered within cell nuclei, released by cell injury, and inactivated by caspase-1 cleavage (27–29). Along with IL-1α, IL-33 is considered an alarmin (indicator of cell damage) (30).

Dissection of TLR and NLR signals involved the convergence of two distinct lines of research. Toll and spätzle, the index TLR family receptor/ligand pair, were discovered as regulators of Dro-
Figure 2
Innate recognition of infection or tissue injury. Endogenous DAMPs such as HSP or exogenous bacterial PAMPs activate the innate immune cells of the CNS by engaging cell surface receptors such as TLRs. Ligation of TLRs initiates an intracellular signaling cascade that involves activation of NF-κB and MAPK activity, which leads to formation of transcription factor AP1. Together these components drive transcription of IL-1 family cytokine precursor proteins pro–IL-1β and pro–IL-18. NLRs are activated by cytosolic microbial products, changes in cytosolic pH, or potassium levels often associated with stimulation of the ligand-gated ion channel P2X7R by extracellular ATP. NLRs such as NALP3 are central constituents of inflammasomes, multiprotein complexes that mediate activation of caspase-1, which catalyzes cleavage and maturation of IL-1 family cytokines. Functional domains of inflammasome components include caspase activation and recruitment domains (CARDs), which are present in both caspase-1 and the adapter apoptosis-associated Speck-like protein containing CARD (ASC). PYD, pyrin domain.

Innate recognition of tissue injury: variation on a theme
TLRs and NLRs are also highly effective at sensing and responding to non-infectious sterile tissue injury, as observed in stroke or trauma (Figure 2). Just as pathogens are detected by virtue of releasing “stranger” signals, so do damaged cells release “danger” signals, designated damage-associated molecular patterns (DAMPs). TLRs and NLRs sense DAMPs: TLR3, TLR7, and TLR9 detect microbial nucleic acids and also those released from necrotic cells (39). TLR2 and TLR4 respond to cell-surface hsp such as Hsp60, Hsp70, and αB crystallin. NLRs can be activated by endogenous cellular products such as uric acid crystals (as in gouty arthritis) and aggregated peptides (20, 40). ATP from damaged cells activates purinergic receptor-regulated channels to cause cytosolic ion fluxes that are detected by NLRs (41, 42).

Cellular soldiers of CNS innate immunity
Microglia. Microglia, the archetypal cells of CNS innate immunity (43), are a unique myeloid cell population, derived from the yolk sac during a narrow time window before vascularization or definitive hematopoiesis in the embryo (44). Once established in the CNS parenchyma, microglia are sustained by proliferation of resident progenitors, independent of blood cells (45). In vitro, microglial activation by diverse stimuli (46) induces varied programs of gene expression, yet these gene-expression patterns have not been validated in vivo (47). Activation of microglia is accompanied by morphological changes (Figure 3 and ref. 48). Despite their dissimilar embryonic origins, microglia are related to resident tissue macrophages. Monocyte-derived macrophages are classified as M1, M2a, M2b, and M2c subsets (49, 50). It is plausible that microglia also transcribe context-dependent, activation-related genes that confer unique phenotypes, however the M1/M2 paradigm has not been extended to any tissue-resident macrophages, let alone a population as unusual as microglia. Repurposing techniques including parabiosis (51) might help in accurately defining subsets of microglia (reviewed in ref. 52).

Systemic inflammation also activates microglia (53–57). Paradoxically, microglial responses to innate stimuli such as systemic LPS show interesting neuroprotective properties in experimental systems. In this paradigm, (stress preconditioning), systemic challenges elicit cytokine responses, which activate microglia and ameliorate injury after subsequent CNS insults including stroke or physical trauma (58–61). The molecular bases and clinical relevance of stress preconditioning remain uncertain.

Chronic neurodegeneration also leads to microglial activation, although the outcome of the activation may be beneficial, deleterious, or neutral. Neurons constitutively express cell-surface and secreted microglial inhibitors; it is conceivable that neuronal cell
death or injury removes this suppression (46). If so, the microglial response to neurodegeneration represents a specialized danger signal. Genetic models have unraveled certain microglial contributions to neurodegeneration. In a genetic mouse model of motor neuron disease, targeted deletion of the causative mutant superoxide dismutase gene in microglia remarkably prolonged the lifespan of the mice even though the mutant transgene was still expressed by neurons and astrocytes (62). Targeted ablation of the CX3CR1 chemokine receptor gene (expressed in the CNS only by microglia) modulates microglial reactivity, in most cases increasing cytokine production and effector functions (63). CX3CR1-deficient mice show enhanced amyloid clearance in Alzheimer’s disease (AD) amyloid deposition models (64), consistent with beneficial activation of microglia (52, 63, 65, 66). By contrast, CX3CR1 deficiency worsens toxicity in τ hyperphosphorylation models (67) and in models incorporating both pathologies, and complex effects are seen in models incorporating both pathologies (68). Amyloid β, the principal component of AD-associated amyloid, directly activates microglia through the NALP3 inflammasome pathway (36), and subsequent production of IL-1β may worsen neurodegeneration (69).

Astrocytes. With the exception of microglia and mast cells, CNS resident cells descend from neuroepithelial stem cells and are categorized as neurons and glia, with glia further subdivided into astrocytes, oligodendrocytes, and polymicroglia. A traditional view holds that glia exist to serve and protect neurons. However, neurons and glia function in intimate interconnections to support every aspect of brain development and function (as reviewed in refs. 70–74). Astrocytes are the best-characterized innate immune neuroglia. The main functions of astrocytes include buffering CNS potassium, removing and recycling potentially toxic glutamate, adjusting water balance, and modulating synaptic activity and blood flow. Astrocytes also produce neurotrophins and anti-inflammatory cytokines such as IL-10 (75).

Upon activation by TLR and NLR signals, astrocytes participate in innate immune reactions and are the principal CNS sources of innate inflammatory mediators, including several complement components, IL-1β, IL-6, and chemokines such as CCL2, CXCL1, CXCL10, and CXCL12 (76–89). Essential homeostatic functions of astrocytes are compromised during inflammatory reactions, potentially worsening outcomes. For example, CXCL12 signaling to astrocytes promotes physiological release of glutamate during synaptic transmission, and also induces release of small amounts of TNF-α. In inflammatory conditions, CXCL12 plus TNF-α signal to microglia to produce large quantities of TNF-α. This cytokine, at high concentrations, impairs the capacity of astrocytes to detoxify glutamate, resulting in neuronal loss through a mechanism termed “excitotoxicity” (79, 90, 91). Microglial-astrocyte interactions are also critical in CNS innate immunity. The deciphering of microglial-astrocyte communication at the molecular level is still in its infancy but already shows promise for identifying interesting therapeutic targets (92, 93).

In a mouse model, the inflammatory transcriptional regulator NF-κB was silenced in astrocytes by transgenic overexpression of a naturally occurring NF-κB inhibitor (94). The blocking of NF-κB signaling in astrocytes showed benefit in disease and injury models—reduced retinal ganglion cell death after ischemic injury; improved recovery from spinal cord trauma, along with increased axonal sparing and regeneration; and lessened inflammation in EAE, a rodent model of the human inflammatory demyelinating disease MS. These findings highlighted the contributions of astrocyte-specific inflammatory signaling for a multitude of CNS pathologies (94–98).

Interactions between innate immune cells and T cells in the CNS

CNS innate immune cells respond to primed T cells and their cytokine directives. Under T cell–mediated inflammatory conditions, the CNS admits large numbers of peripheral innate immune cells. Indeed, CNS infiltration by peripheral cells is critical for protective host defense against infection and for repair after stroke or physical trauma (99–104). However, restraint is required because hematogenous inflammation causes profound damage if the reaction is excessive or inappropriate. The interaction of the CNS innate immune system with infiltrating T cells is typified by MS and EAE (reviewed in refs. 105, 106). EAE can be induced by actively immunizing rodents with myelin protein peptides, which are emulsified...
Thus it is likely that, in MS as in EAE, disease-causing autoreactive CD4 T cells are reactivated in the CNS by cognate antigen, release of stimulating and angiogenic factors, lytic enzymes, and antimicrobial mast cell responses involve the release of TNF-α and IL-1β. When neutrophils are reactivated in the CNS by cognate antigen, release of neutrophils is required to recruit CD11b+ neutrophils, which are often associated with unfavorable outcomes, potentially because of the severity of the infection (125). Roles of neutrophils in chronic sterile neuroinflammation (as in MS) are under investigation. G-CSF, a growth factor that supports neutrophil activation, worsens MS disease activity (126). Neutrophils are not detected in postmortem MS tissues, nor are there increased neutrophils in the blood or CSF of MS patients (127). By contrast, lesions of neuromyelitis optica (NMO), an autoimmune CNS disease caused by aquaporin 4 antibodies, show abundant neutrophils, which may also be found in CSF during active disease (128). Variable acuity of NMO and MS may contribute to these different findings. NMO lesions are much more destructive and more likely to cause death during acute disease, whereas fatal outcomes of MS occur through complications of immobility after decades of disease. Therefore, the absence of neutrophils in lesions of MS (studied at autopsy) may not be proof of their absence during lesion formation.

Animal models also implicate neutrophil involvement in MS. In EAE, neutrophils are among the earliest CNS-infiltrating cells (129, 130), and neutrophil depletion reduces EAE severity dramatically (131). Furthermore, CXCR2–/– mice are resistant to EAE induction (131, 132). Neutrophil influx into the CNS during EAE results from TNF-α production by meningeal mast cells (133). Because neutrophils also promote B cell survival and proliferation (120), innate neutrophils and mast cells might contribute to the B cell follicle-like structures that are found at autopsy in the meninges of MS tissues (134, 135).

**Mast cells**

Mast cells are myeloid cells defined by c-kit+ FcεRI+ expression and are well known for roles in allergic disease and host defense (136, 137). Mast cells are particularly numerous within tissues exposed to the external environment, such as skin, gut, and respiratory tract, but are also found in brain, spinal cord, and meninges. Classic antimicrobial mast cell responses involve the release of TNF-α and IL-1β (136, 138–140).

Collectively, mast cells comprise a large population of CNS cells, yet they are fixed and widely dispersed, which poses hurdles for direct study. Nevertheless, provocative correlative findings have been reported that implicate these cells in CNS inflammation. Mast cells are present in active MS plaques (141, 142), and mast cell–specific transcripts encoding tryptase and FceRI are detected in lesions of chronic MS (143). Tryptase and histamine are present in the CSF of MS patients but not healthy individuals (144, 145). Mast cells in the CNS parenchyma likely contribute to local inflammatory responses, and CNS mast cells appear to exert both neuroprotective and damaging effects following concussion injury or stroke (146).

There are limitations to the commonly used experimental models that utilize c-kit– mutant, mast cell–deficient mice (147) for the study of mast cell function, as mast cell development is exquisitely dependent on SCF signaling through c-kit. Mice with reduced SCF signaling due to mutations in the c-kit receptor (W/Wv or Wsh mice) exhibit a loss of mast cells. Mast cells can be reconstituted by systemic or local transfer of bone marrow–derived mast cell precursors in mice harboring c-kit mutations. The c-kit– mutant mice have additional hematologic and developmental abnormalities, and it is therefore essential to use mast cell reconstitution to confirm that the observed phenotypic differences between wild type and Kit mutant mice are mast cell dependent (148, 149). Unfortunately, transfused mast cells fail to reconstitute the brains and spinal cords of c-kit mutant mice, making it challenging to use this model to address the functions of CNS-resident mast cells in health or disease (147).
Initial EAE studies using c-kit<sup>−/−</sup> or c-kit<sup>Wt/wt</sup> mice employed diverse disease-induction protocols and subjective neurobehav-
itoral scoring, yielding inconsistent and conflicting conclusions about EAE severity in mast-cell–deficient mice (150–153).

Objective, quantitative disease severity measures revealed that mast cells were critical for fulminating disease in both chronic (C57BL/6-MOG<sub>35–55</sub>-induced) and relapsing remitting (SJL-JPLP<sub>100–135</sub>-induced) EAE (133, 154). BBB integrity was enhanced and decreased inflammatory cell infiltrates were decreased in c-kit<sup>−/−</sup> mice with EAE, as compared with wild-type animals (133).

Interestingly, TNF-α production by dura mater and pia mater mast cells regulates BBB function as well as T cell and myeloid cell infiltration into the CNS (133), consistent with the idea that these mast cells are protective first responders to microbial CNS challenge, as they are in the periphery.

During the preclinical phase of EAE, T cells interact with APCs and proliferate in the leptomeninges around the spinal cord, suggesting that the leptomeninges is a site of T cell reactivation (155–158). Given that mast cells direct immune cell traffic to peripheral sites of infec-

Summary
The immune-privileged status of the CNS has evolved to main-
tain homeostasis required for neural function and host defense.

The inability to generate robust and potentially harmful adap-
tive immune responses therefore requires a primary reliance for host defense on the sequestered and moderate innate responses of microglia, astrocytes, and other resident innate cells. Nonetheless, pathologic neuroinflammation is inherent in all diseases that disrupt CNS tissue elements, including MS, AD, Parkinson’s dis-

ease, stroke, and traumatic brain injury. Our understanding of the interactions between resident and peripheral immune cells, neu-
rons, and glial cells and their implications for host defense, tissue repair, and neurodegeneration is still in its infancy. However, the delineation of the molecular interactions between the immune and CNS systems is proceeding rapidly and will yield translational applications in the years to come.

Acknowledgments
Research in the Ranoshoff lab is supported by the NIH (grants R01NS132151, R21NS78420, and K24NS151400), the National MS Society (RG4550), gifts from the Walker and Warren families, and the Williams Family Foundation for MS Research.

Address correspondence to: Richard M. Ranoshoff, Neuroinflam-
mation Research Center, Lerner Research Institute, Cleveland Clinic, Mail Code NC30, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA.

Phone: 216.444.0627; Fax: 216.444.7927; E-mail: ranosrh@ccf.org.


2. Dudda JC, et al. Dendritic cells govern induction and reprogramming of polarized tissue-specific homing receptor patterns of T cells: important roles for soluble factors and tissue microenviron-


4. Oyoshi MK, et al. Epicutaneous challenge of murine mast cells generates antigen-specific cytotoxic T cell responses in the CNS by myeloid dendritic cells: critical participants in CNS neuroinflammation now appears critical for identifying effective and comprehensive therapies for CNS diseases. The ongoing development of novel genetic murine models with selective mast cell defects will help toward this goal (160).

5. Almolda B, Gonzalez B, Castellano B. Antigen presentation in the CNS by myeloid dendritic cells: critical participants in CNS neuroinflammation now appears critical for identifying effective and comprehensive therapies for CNS diseases. The ongoing development of novel genetic murine models with selective mast cell defects will help toward this goal (160).

10. Almolda B, Gonzalez B, Castellano B. Antigen presentation in the CNS by myeloid dendritic cells: critical participants in CNS neuroinflammation now appears critical for identifying effective and comprehensive therapies for CNS diseases. The ongoing development of novel genetic murine models with selective mast cell defects will help toward this goal (160).

25. Martinon F, Gaide O, Petrilli V, Mayor A, Tschopp J. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentra-

33. Lehnardt S. Innate immunity and neuroinflam-


7. Miller SD, McMahon EJ, Bailey SL, Miller SD. CNS dendritic cells: critical participa-

2. Dudda JC, et al. Dendritic cells govern induction and reprogramming of polarized tissue-specific homing receptor patterns of T cells: important roles for soluble factors and tissue microenviron-

5. Almolda B, Gonzalez B, Castellano B. Antigen presentation in the CNS by myeloid dendritic cells: critical participants in CNS neuroinflammation now appears critical for identifying effective and comprehensive therapies for CNS diseases. The ongoing development of novel genetic murine models with selective mast cell defects will help toward this goal (160).

10. Almolda B, Gonzalez B, Castellano B. Antigen presentation in the CNS by myeloid dendritic cells: critical participants in CNS neuroinflammation now appears critical for identifying effective and comprehensive therapies for CNS diseases. The ongoing development of novel genetic murine models with selective mast cell defects will help toward this goal (160).

25. Martinon F, Gaide O, Petrilli V, Mayor A, Tschopp J. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentra-


